APGE vs. KYMR, VCEL, DNLI, RXRX, BEAM, DNA, TWST, CGON, FUSN, and INBX
Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Kymera Therapeutics (KYMR), Vericel (VCEL), Denali Therapeutics (DNLI), Recursion Pharmaceuticals (RXRX), Beam Therapeutics (BEAM), Ginkgo Bioworks (DNA), Twist Bioscience (TWST), CG Oncology (CGON), Fusion Pharmaceuticals (FUSN), and Inhibrx (INBX). These companies are all part of the "biological products, except diagnostic" industry.
Apogee Therapeutics (NASDAQ:APGE) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership.
Apogee Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics.
In the previous week, Apogee Therapeutics had 7 more articles in the media than Kymera Therapeutics. MarketBeat recorded 10 mentions for Apogee Therapeutics and 3 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.85 beat Apogee Therapeutics' score of 0.64 indicating that Kymera Therapeutics is being referred to more favorably in the news media.
Apogee Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -194.67%. Apogee Therapeutics' return on equity of 0.00% beat Kymera Therapeutics' return on equity.
79.0% of Apogee Therapeutics shares are held by institutional investors. 36.1% of Apogee Therapeutics shares are held by company insiders. Comparatively, 15.8% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Apogee Therapeutics currently has a consensus target price of $73.00, indicating a potential upside of 37.17%. Kymera Therapeutics has a consensus target price of $41.10, indicating a potential upside of 6.06%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Apogee Therapeutics is more favorable than Kymera Therapeutics.
Kymera Therapeutics received 24 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 47.56% of users gave Kymera Therapeutics an outperform vote.
Summary
Apogee Therapeutics beats Kymera Therapeutics on 11 of the 14 factors compared between the two stocks.
Get Apogee Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apogee Therapeutics Competitors List
Related Companies and Tools
